hotspot -WSS

hotspot

author：knowledge 2025-09-30 23:39:08 - browse：3

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： NVIDIA and Google execs on the future of AI and drug discovery

WSS

Traditional Chinese medicine benefits explored in new JAMA study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Chimpanzees, like humans and whales, get menopause: Study

Testing for cancer recurrence creates a new limbo for patients

Wearables generate powerful data but its not useful to doctors, yet

Second House panel advances two

focus

hotspot

Wikipedia

Medicare details structure of new drug price negotiation program

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Alkermes shareholders re

FDA has safety concerns on CRISPR

Psychedelics group wrestles with new pharma identity

Diversifying clinical trials isn't enough to close racial gaps: study

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: XBI biotech index, Akero Therapeutics

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Testing for cancer recurrence creates a new limbo for patients

focus

Case highlights the risks of experimental stem cell therapy

Glen Campbell's doctor discusses his public struggle with Alzheimer's

The FDA weighs the risks of candy

Cassava reveals details — and problems — with Alzheimer's study

Testing for cancer recurrence creates a new limbo for patients

Traditional Chinese medicine benefits explored in new JAMA study

leisure time

knowledge

entertainment

Wikipedia